Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
PIONEER TEENS is the first clinical trial of an oral GLP-1 in children & adolescents 10–17 years with type 2 diabetes, addressing a significant unmet need
Eli Lilly Is More Than GLP-1 Drugs. The Stock Looks Attractive.
02:42pm, Wednesday, 22'nd Apr 2026
The acquisition of Kelonia Therapeutics, announced this week, is part of Lilly's expansion into cancer treatments.
Ceasefire extension, Best Buy's new CEO, Amazon's GLP-1 push and more in Morning Squawk
08:22am, Wednesday, 22'nd Apr 2026
Here are five key things investors need to know to start the trading day.
Amazon.com to Offer Program for GLP-1 Weight-Loss Drugs
03:33pm, Tuesday, 21'st Apr 2026
Amazon One Medical members can get Novo Nordisk's Wegovy and Eli Lilly's Foundayo GLP-1 pills in a program that integrates primary-care services with the technology company's pharmacy business.
Amazon shakes GLP-1 race as Eli Lilly, Novo Nordisk stocks fall
03:31pm, Tuesday, 21'st Apr 2026
Amazon is expanding its footprint in healthcare, unveiling a new program aimed at simplifying access to weight-loss treatments and reshaping how GLP-1 drugs are delivered to patients. The move positio
Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50
01:54pm, Tuesday, 21'st Apr 2026
Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for GLP-1 medications for weight loss.
Amazon launches GLP-1 weight loss program, promising 'fast, convenient' access
01:20pm, Tuesday, 21'st Apr 2026
Amazon One Medical launched a GLP-1 program integrating obesity care with Amazon Pharmacy. Pricing for the popular weight loss drugs will begin at as low as $25 per month with insurance.
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
09:10am, Tuesday, 21'st Apr 2026
600,000 New Wegovy® Pill Prescriptions Written in First Two Months Kelowna, British Columbia – April 21, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “
BODi Expands GLP-1 Support and Longevity-Driven Fitness with “10 Minute BODi” Workouts
08:00am, Tuesday, 21'st Apr 2026
EL SEGUNDO, Calif.--(BUSINESS WIRE)--BODi (NASDAQ: BODI) today announced the expansion of its 10 Minute BODi catalogue with three new digital programs, accelerating its push to make consistent fitness
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
11:20am, Friday, 17'th Apr 2026
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingl
Omada Health Helps Members on GLP‑1s Lose More Fat, Preserve Muscle Mass, and Improve Mental Health, New Study Finds
09:00am, Friday, 17'th Apr 2026
SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, announced new study results demonstrating that Omada members in its GLP
Lilly's new GLP-1 pill is off to a ‘robust' start
08:28am, Friday, 17'th Apr 2026
Lilly's new GLP-1 pill had 1,390 prescriptions in its first week on the market.
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
01:44pm, Thursday, 16'th Apr 2026
Investors are starting to focus on what will replace compounded GLP-1 driven growth for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth vector, d
Hims & Hers Health Stock Rallies on Regulatory Pivot. It's Not About GLP-1s This Time.
08:46am, Thursday, 16'th Apr 2026
Hims has signaled its interest in peptides, many of which have been banned for use in compounding pharmacies.
Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes
05:58pm, Tuesday, 14'th Apr 2026
Hims & Hers has sharply declined, losing nearly 40% YTD and two-thirds from last year's peak. Despite the selloff, I see compelling value in HIMS at its current, compressed valuation. Markets have pen
